[A19-99] Pembrolizumab (combination with axitinib, renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 02.03.2020
Commission awarded on 02.12.2019 by the Federal Joint Committee (G-BA).
Treatment-naive adults with advanced renal cell carcinoma
Indication of considerable added benefit both in favourable or intermediate and in poor risk profile
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.